CoChat
Sign Up
Cited by 1,900Bone health and osteoporosis researchMenopause: Health Impacts and TreatmentsHip and Femur Fractures

European guidance for the diagnosis and management of osteoporosis in postmenopausal women

Open access
on behalf of the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF), Kanis, J.A., Cooper, C., Rizzoli, R., Reginster, J.-Y.·2019·Osteoporosis International
DOI 10.1007/s00198-018-4704-5PMC PMC7026233
Open this paper in CoChat — free accountOpen PDF

Abstract

Guidance is provided in a European setting on the assessment and treatment of postmenopausal women at risk from fractures due to osteoporosis. The International Osteoporosis Foundation and European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis published guidance for the diagnosis and management of osteoporosis in 2013. This manuscript updates these in a European setting. Systematic reviews were updated. The following areas are reviewed: the role of bone mineral density measurement for the diagnosis of osteoporosis and assessment of fracture risk; general and pharmacological management of osteoporosis; monitoring of treatment; assessment of fracture risk; case-finding strategies; investigation of patients; health economics of treatment. The update includes new information on the evaluation of bone microstructure evaluation in facture risk assessment, the role of FRAX® and Fracture Liaison Services in secondary fracture prevention, long-term effects on fracture risk of dietary intakes, and increased fracture risk on stopping drug treatment. A platform is provided on which specific guidelines can be developed for national use.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00198-018-4704-5

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 373 · Cited by 1,900

Research works printed but not linked: 340

  1. [1]Kanis JA Delmas P Burckhardt P Cooper C Torgerson D Guidelines for diagnosis and management of osteoporosis. The European Foundation for Osteoporosis and Bone Disease Osteoporos Int 1997 7 390 406 9373575
  2. [2]Kanis JA Burlet N Cooper C Delmas PD Reginster JY Borgstrom F Rizzoli R European guidance for the diagnosis and management of osteoporosis in postmenopausal women Osteoporos Int 2008 19 399 428 18266020 PMC2613968
  3. [3]Kanis JA McCloskey EV Johansson H Cooper C Rizzoli R Reginster J-Y on behalf of the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF) European guidance for the diagnosis and management of osteoporosis in postmenopausal women Osteoporos Int 2013 24 23 57 23079689 PMC3587294
  4. [4]Hernlund E, Svedbom A, Ivergård M, Ivergård M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jönsson B, Kanis JA (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Archives of Osteoporosis 8:136. 10.1007/s11657-013-0136-1. Access: http://www.iofbonehealth.org/data-publications/regional-audits/osteoporosis-european-union-medical-management-epidemiology-and Accessed 4 Jan 2018 PMC3880487 24113837 · DOI
  5. [5]Kanis JA Svedbom A Harvey N McCloskey EV The osteoporosis treatment gap J Bone Miner Res 2014 29 1926 1928 24956507
  6. [6]Kim SC Kim DH Mogun H Eddings W Polinski JM Franklin JM Solomon DH Impact of the U.S. Food and Drug Administration’s safety-related announcements on the use of bisphosphonates after hip fracture J Bone Miner Res 2016 31 1536 1540 26969902 PMC5040596
  7. [7]Elliot-Gibson V Bogoch ER Jamal SA Beaton DE Practice patterns in the diagnosis and treatment of osteoporosis after a fragility fracture: a systematic review Osteoporos Int 2004 15 767 778 15258724
  8. [8]Giangregorio L Papaioannou A Cranney A Zytaruk N Adachi JD Fragility fractures and the osteoporosis care gap: an international phenomenon Semin Arthritis Rheum 2006 35 293 305 16616152
  9. [9]Haaland DA Cohen DR Kennedy CC Khalidi NA Adachi JD Papaioannou A Closing the osteoporosis care gap: increased osteoporosis awareness among geriatrics and rehabilitation teams BMC Geriatr 2009 9 28 19602246 PMC2731027
  10. [10]Consensus Development Conference Diagnosis, prophylaxis, and treatment of osteoporosis Am J Med 1993 94 646 650 8506892
  11. [11]World Health Organization Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group World Health Organ Tech Rep Ser 1994 843 1 129 7941614
  12. [13]Nguyen T Sambrook P Kelly P Jones G Lord S Freund J Eisman J Prediction of osteoporotic fractures by postural instability and bone density BMJ 1993 307 1111 1115 8251809 PMC1679116
  13. [14]Kanis JA Johnell O Odén A Sembo I Redlund-Johnell I Dawson A De Laet C Jonsson B Long-term risk of osteoporotic fracture in Malmo Osteoporos Int 2000 11 669 674 11095169
  14. [15]Cooper C, Atkinson EJ, Jacobsen SJ, O’Fallon WM, Melton LJ, 3rd (1993) Population-based study of survival after osteoporotic fractures. Am J Epidemiol 137:1001–1005 8317445
  15. [16]Kanis JA Odén A Johnell O De Laet C Jonsson B Oglesby AK The components of excess mortality after hip fracture Bone 2003 32 468 473 12753862
  16. [17]Johnell O Kanis JA An estimate of the worldwide prevalence and disability associated with osteoporotic fractures Osteoporos Int 2006 17 1726 1733 16983459
  17. [18]Blake G, Adams JE, Bishop N (2013) DXA in adults and children. Primer on the metabolic bone diseases and disorders of mineral metabolism, 8th edition. Ed Rosen CJ, Chapter 30, pp 249–263. John Wiley & Sons,
  18. [19]Glüer CC (2013) Quantitative computed tomography in children and adults. Primer on the metabolic bone diseases and disorders of mineral metabolism, 8th edition. Ed Rosen CJ, Chapter 31, pp 264–276. John Wiley & Sons,
  19. [20]Majumdar S (2013) Magnetic resonance imaging of bone. Primer on the metabolic bone diseases and disorders of mineral metabolism, 8th edition. Ed Rosen CJ, Chapter 32, pp 277–282. John Wiley & Sons,
  20. [21]Gary JR, Cook G, Gnanasegaran G, Fogelman I (2013) Radionuclide scintigraphy in metabolic bone disease. In: Primer on the metabolic bone diseases and disorders of mineral metabolism, 8th edition. Ed Rosen CJ, chapter 33, pp. John Wiley & Sons, pp 283–288
  21. [22]Johannesdottir F Thrall E Muller J Keaveny TM Kopperdahl DL Bouxsein ML Comparison of non-invasive assessments of strength of the proximal femur Bone 2007 105 93 102 28739416
  22. [23]Silva BC Leslie WD Resch H Lamy O Lesnyak O Binkley N McCloskey EV Kanis JA Bilezikian JP Trabecular bone score: a non-invasive analytical method based upon the DXA image J Bone Miner Res 2014 29 518 530 24443324
  23. [24]Edmondson CP Schwartz EN Non-BMD DXA measurements of the hip Bone 2017 104 73 83 28476576
  24. [25]Leslie WD Lix LM Majumdar SR Morin SN Johansson H Odén A McCloskey EV Kanis JA Total hip bone area affects fracture prediction with FRAX in Canadian white women J Clin Endocrinol Metab 2017 102 4242 4249 29092086
  25. [26]Bala Y, Zebaze R, Ghasem-Zadeh A, Atkinson EJ, Iuliano S, Peterson JM, Amin S, Bjørnerem Å, Melton LJ 3rd, Johansson H, Kanis JA, Khosla S, Seeman E (2014) Cortical porosity identifies women with osteopenia at increased risk for forearm fractures. J Bone Miner Res 26:1356–1362 PMC4156822 24519558
  26. [27]Zebaze R Ghasem-Zadeh A Mbala A Seeman E A new method of segmentation of compact-appearing, transitional and trabecular compartments and quantification of cortical porosity from high resolution peripheral quantitative computed tomographic images Bone 2013 54 8 20 23334082
  27. [28]Schousboe JT, Ensrud KE, Nyman JA, Kane RL, Melton LJ, 3rd (2006) Cost-effectiveness of vertebral fracture assessment to detect prevalent vertebral deformity and select postmenopausal women with a femoral neck T-score >−2.5 for alendronate therapy: a modeling study. J Clin Densitom 9:133–143 16785071
  28. [29]McCloskey EV Vasireddy S Threlkeld J Eastaugh J Parry A Bonnet N Beneton M Kanis JA Charlesworth D Vertebral fracture assessment (VFA) with a densitometer predicts future fractures in elderly women unselected for osteoporosis J Bone Miner Res 2008 23 1561 1568 18505372
  29. [30]Lee JH Lee YK Oh SH Ahn J Lee YE Pyo JH Choi YY Kim D Bae SC Sung YK Kim DY A systematic review of diagnostic accuracy of vertebral fracture assessment (VFA) in postmenopausal women and elderly men Osteoporos Int 2016 27 1691 1699 26782682
  30. [31]Lewiecki EM Bone densitometry and vertebral fracture assessment Curr Osteoporos Rep 2010 8 123 130 20556673
  31. [32]Marshall D Johnell O Wedel H Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures BMJ 1996 312 1254 1259 8634613 PMC2351094
  32. [33]Gluer CC Quantitative ultrasound techniques for the assessment of osteoporosis: expert agreement on current status. The International Quantitative Ultrasound Consensus Group J Bone Miner Res 1997 12 1280 1288 9258759
  33. [34]Kanis JA Melton LJ 3rd Christiansen C Johnston CC Khaltaev N The diagnosis of osteoporosis J Bone Miner Res 1994 9 1137 1141 7976495
  34. [35]Watts NB Fundamentals and pitfalls of bone densitometry using dual-energy X-ray absorptiometry (DXA) Osteoporos Int 2004 15 847 854 15322740
  35. [37]Kanis JA, McCloskey EV, Johansson H, Odén A, Melton LJ, 3rd, Khaltaev N (2008) A reference standard for the description of osteoporosis. Bone 42: 467–475 18180210
  36. [38]Ferrari S Bianchi ML Eisman JA Foldes AJ Adami S Wahl DA Stepan JJ de Vernejoul MC Kaufman JM Osteoporosis in young adults: pathophysiology, diagnosis, and management Osteoporos Int 2012 23 2735 2748 22684497
  37. [39]Kanis JA Gluer CC An update on the diagnosis and assessment of osteoporosis with densitometry. Committee of Scientific Advisors, International Osteoporosis Foundation Osteoporos Int 2000 11 192 202 10824234
  38. [40]De Laet CEDH, Van Hout BA, Burger H, Hofman A, Weel AE, Pols H (1998) Hip fracture prediction in elderly men and women: validation in the Rotterdam study. J Bone Miner Res 13: 1587–1593 9783547
  39. [41]Johnell O, Kanis JA, Odén A, Johansson H, De Laet C, Delmas P, Eisman JA, Fujiwara S, Kroger H, Mellstrom D, Meunier PJ, Melton LJ 3rd, O’Neill T, Pols H, Reeve J, Silman A, Tenenhouse A (2005) Predictive value of BMD for hip and other fractures. J Bone Miner Res 20: 1185–1194 15940371
  40. [42]Kanis JA Bianchi G Bilezikian JP Kaufman JM Khosla S Orwoll E Seeman E Towards a diagnostic and therapeutic consensus in male osteoporosis Osteoporos Int 2011 22 2789 2798 21509585 PMC3555694
  41. [43]Lewiecki EM, Watts NB, McClung MR, Petak SM, Bachrach LK, Shepherd JA, Downs RW, Jr. (2004) Official positions of the international society for clinical densitometry. J Clin Endocrinol Metab 89:3651–3655 15292281
  42. [44]Binkley N Bilezikian JP Kendler DL Leib ES Lewiecki EM Petak SM Official positions of the International Society for Clinical Densitometry and Executive Summary of the 2005 Position Development Conference J Clin Densitom 2006 9 4 14 16731426
  43. [45]Blake GM Patel R Knapp KM Fogelman I Does the combination of two BMD measurements improve fracture discrimination? J Bone Miner Res 2003 18 1955 1963 14606507
  44. [46]Kanis JA, Johnell O, Odén A, Johansson H, Eisman JA, Fujiwara S, Kroger H, Honkanen R, Melton LJ 3rd, O’Neill T, Reeve J, Silman A, Tenenhouse A (2006) The use of multiple sites for the diagnosis of osteoporosis. Osteoporos Int 17: 527–534 16402164
  45. [47]Leslie WD Lix LM Tsang JF Caetano PA Single-site vs multisite bone density measurement for fracture prediction Arch Intern Med 2007 167 1641 1647 17698687
  46. [48]Odén A McCloskey EV Johansson H Kanis JA Assessing the impact of osteoporosis on the burden of hip fractures Calcif Tissue Int 2013 92 42 49 23135744
  47. [49]Kanis JA Johnell O Odén A Dawson A De Laet C Jonsson B Ten-year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds Osteoporos Int 2001 12 989 995 11846333
  48. [50]Cummings SR Black DM Nevitt MC Browner W Cauley J Ensrud K Genant HK Palermo L Scott J Vogt TM Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group Lancet 1993 341 72 75 8093403
  49. [51]Moayyeri A Adams JE Adler RA Krieg MA Hans D Compston J Lewiecki EM Quantitative ultrasound of the heel and fracture risk assessment: an updated meta-analysis Osteoporos Int 2012 23 143 153 22037972
  50. [52]McCloskey EV Kanis JA Odén A Harvey NC Bauer D González-Macias J Hans D Kaptoge S Krieg MA Kwok T Marin F Moayyeri A Orwoll E Gluёr C Johansson H Predictive ability of heel quantitative ultrasound for incident fractures: an individual-level meta-analysis Osteoporos Int 2015 26 1979 1987 25690339
  51. [54]Ribot C Pouilles JM Bonneu M Tremollieres F Assessment of the risk of post-menopausal osteoporosis using clinical factors Clin Endocrinol 1992 36 225 228 1563075
  52. [55]Poor G Atkinson EJ O’Fallon WM Melton LJ 3rd Predictors of hip fractures in elderly men J Bone Miner Res 1995 10 1900 1907 8619370
  53. [56]Kanis JA Diagnosis of osteoporosis and assessment of fracture risk Lancet 2002 359 1929 1936 12057569
  54. [57]Hui SL Slemenda CW Johnston C Age and bone mass as predictors of fracture in a prospective study J Clin Invest 1988 81 1804 1809 3384952 PMC442628
  55. [58]Kanis JA, Johansson H, Odén A, Johnell O, De Laet C, Eisman JA, McCloskey EV, Mellstrom D, Melton LJ 3rd, Pols HA, Reeve J, Silman AJ, Tenenhouse A (2004) A family history of fracture and fracture risk: a meta-analysis. Bone 35: 1029–1037 15542027
  56. [59]Kanis JA Johansson H Odén A Johnell O de Laet C Melton LJ III Tenenhouse A Reeve J Silman AJ Pols HA Eisman JA McCloskey EV Mellstrom D A meta-analysis of prior corticosteroid use and fracture risk J Bone Miner Res 2004 19 893 899 15125788
  57. [60]Kanis JA Johansson H Johnell O Odén A De Laet C Eisman JA Pols H Tenenhouse A Alcohol intake as a risk factor for fracture Osteoporos Int 2005 16 737 742 15455194
  58. [61]Kanis JA Johnell O Odén A Johansson H De Laet C Eisman J Smoking and fracture risk: a meta-analysis Osteoporos Int 2005 16 155 162 15175845
  59. [63]Klotzbuecher CM Ross PD Landsman PD Abbott TA Berger M Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis J Bone Miner Res 2000 15 721 739 10780864
  60. [64]Kanis JA Johnell O De Laet C Johansson H Oden A Delmas P Eisman J Fujiwara S Garnero P Kroger H McCloskey EV Mellstrom D Melton LJ Pols H Reeve J Silman A Tenenhouse A A meta-analysis of previous fracture and subsequent fracture risk Bone 2004 35 375 382 15268886
  61. [65]Kanis JA McCloskey E Johansson H Odén A Leslie WD FRAXwith and without bone mineral density Calcif Tissue Int 2012 90 1 13 22057815
  62. [66]Schwartz AV Vittinghoff E Bauer DC Hillier TA Strotmeyer ES Ensrud KE Donaldson MG Cauley JA Harris TB Koster A Womack CR Palermo L Black DM Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes JAMA 2011 305 2184 2192 21632482 PMC3287389
  63. [67]Giangregorio LM Leslie WD Lix LM Johansson H Odén A McCloskey E Kanis JA FRAX underestimates fracture risk in patients with diabetes J Bone Miner Res 2012 27 301 308 22052532
  64. [68]Leslie WD Rubin MR Schwartz AZ Kanis JA Perspective: diabetes and bone J Bone Miner Res 2012 27 2231 2237 23023946
  65. [69]Nguyen ND Frost SA Center JR Eisman JA Nguyen TV Development of prognostic nomograms for individualizing 5-year and 10-year fracture risks Osteoporos Int 2008 19 1431 1444 18324342
  66. [70]Hippisley-Cox J Coupland C Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractureScores BMJ 2009 339 b4229 19926696 PMC2779855
  67. [71]McClung MR Geusens P Miller PD Zippel H Bensen WG Roux C Adami S Fogelman I Diamond T Eastell R Meunier PJ Reginster JY Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group N Engl J Med 2001 344 333 340 11172164
  68. [72]Delmas PD Eastell R Garnero P Seibel MJ Stepan J The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation Osteoporos Int 2000 11 Suppl 6 S2 17 11193237
  69. [73]Vasikaran S Eastell R Bruyère O Foldes AJ Garnero P Griesmacher A McClung M Morris HA Silverman S Trenti T Wahl DA Cooper C Kanis JA Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards Osteoporos Int 2011 22 391 420 21184054
  70. [74]Johansson H Odén A Kanis JA McCloskey EV Morris HA Cooper C Vasikaran S A meta-analysis of reference markers of bone turnover for prediction of fracture Calcif Tissue Int 2014 94 560 567 24590144
  71. [75]Morris HA Eastell R Jorgensen NR Cavalier E Vasikaran S Chubb SAP Kanis JA Cooper C Makris K Clinical usefulness of bone turnover marker concentrations in osteoporosis Clin Chim Acta 2017 467 34 41 27374301
  72. [76]Harvey NC Glüer CC Binkley N McCloskey EV Brandi ML Cooper C Kendler D Lamy O Laslop A Camargos BM Reginster JY Rizzoli R Kanis JA Trabecular bone score (TBS) as a new complementary approach for osteoporosis evaluation in clinical practice. A consensus report of a European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) Working Group Bone 2015 78 216 224 25988660 PMC4538791
  73. [77]McCloskey EV Odén A Harvey NC Leslie WD Hans D Johansson H Barkmann R Boutroy S Brown J Chapurlat R Elders PJ Fujita Y Glüer CC Goltzman D Iki M Karlsson M Kindmark A Kotowicz M Kurumatani N Kwok T Lamy O Leung J Lippuner K Ljunggren Ö Lorentzon M Mellström D Merlijn T Oei L Ohlsson C Pasco JA Rivadeneira F Rosengren B Sornay-Rendu E Szulc P Tamaki J Kanis JA A meta-analysis of trabecular bone score in fracture risk prediction and its relationship to FRAX J Bone Miner Res 2016 31 940 948 26498132
  74. [78]Martineau P Leslie WD Johansson H Odén A McCloskey EV Hans D Kanis JA Clinical utility of using lumbar spine trabecular bone score to adjust fracture probability: the Manitoba BMD cohort J Bone Miner Res 2017 32 1568 1574 28276598
  75. [79]Leslie WD Aubry-Rozier B Lix LM Morin SN Majumdar SR Hans D Spine bone texture assessed by trabecular bone score (TBS) predicts osteoporotic fractures in men: the Manitoba Bone Density Program Bone 2014 67 10 14 24998455
  76. [80]McCloskey EV Odén A Harvey NC Leslie WD Hans D Johansson H Kanis JA Adjusting fracture probability by trabecular bone score Calcif Tissue Int 2015 96 500 509 25796374
  77. [81]Leslie WD Johansson H Kanis JA Lamy O Odén A McCloskey EV Hans D Lumbar spine texture enhances 10-year fracture probability assessment Osteoporos Int 2014 25 2271 2277 24951032
  78. [82]Fink HA Milavetz DL Palermo L Nevitt MC Cauley JA Genant HK What proportion of incident radiographic vertebral deformities is clinically diagnosed and vice versa? J Bone Miner Res 2005 20 1216 1222 15940375
  79. [83]Melton LJ 3rd, Atkinson EJ, Cooper C, O’Fallon WM, Riggs BL (1999) Vertebral fractures predict subsequent fractures. Osteoporos Int 10:214–221 10525713
  80. [84]Johansson H Odén A McCloskey EV Kanis JA Mild morphometric vertebral fractures predict vertebral fractures but not non-vertebral fractures Osteoporos Int 2014 25 235 241 23974856
  81. [85]Compston J Cooper A Cooper C Gittoes N Gregson C Harvey N Hope S Kanis JA McCloskey EV Poole KES Reid DM Selby P Thompson F Thurston A Vine N UK clinical guideline for the prevention and treatment of osteoporosis Arch Osteoporos 2017 12 43 28425085 PMC5397452
  82. [86]Kanis JA Harvey NC Johansson H Odén A McCloskey EV Leslie WD Overview of fracture prediction tools J Clin Densitom 2017 20 360 367 28716500 PMC5663341
  83. [87]Kanis JA Johnell O Odén A Johansson H McCloskey E FRAX and the assessment of fracture probability in men and women from the UK Osteoporos Int 2008 19 385 397 18292978 PMC2267485
  84. [88]Kanis JA Johansson H Odén A Cooper C EV l MC Worldwide uptake of FRAX Arch Osteoporos 2014 9 166 10.1007/s11657-013-0166-8 24420978 · DOI
  85. [89]Kanis JA Harvey NC Cooper C Johansson H Odén A McCloskey EV A systematic review of intervention thresholds based on FRAX Arch Osteoporos 2016 11 1 25 27465509 PMC4978487
  86. [90]Kanis JA, Odén A, Johnell O, Johansson H, De Laet C, Brown J, Burckhardt P, Cooper C, Christiansen C, Cummings S, Eisman JA, Fujiwara S, Glüer C, Goltzman D, Hans D, Krieg MA, La Croix A, McCloskey E, Mellstrom D, Melton LJ 3rd, Pols H, Reeve J, Sanders K, Schott AM, Silman A, Torgerson D, van Staa T, Watts NB, Yoshimura N (2007) The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 18:1033–1046 17323110
  87. [91]Kanis JA Johnell O De Laet C Jonsson B Odén A Ogelsby AK International variations in hip fracture probabilities: implications for risk assessment J Bone Miner Res 2002 17 1237 1244 12096837
  88. [92]Kanis JA Hans D Cooper C Baim S Bilezikian JP Binkley N Cauley JA Compston JE Dawson-Hughes B El-Hajj Fuleihan G Johansson H Leslie WD Lewiecki EM Luckey M Odén A Papapoulos SE Poiana C Rizzoli R Wahl DA McCloskey EV Interpretation and use of FRAX in clinical practice Osteoporos Int 2011 22 2395 2411 21779818
  89. [93]Van Staa TP Leufkens HG Abenhaim L Zhang B Cooper C Use of oral corticosteroids and risk of fractures J Bone Miner Res 2000 15 993 1000 10841167
  90. [94]Harvey NC Odén A Orwoll E Lapidus J Kwok T Karlsson MK Rosengren BE Ljunggren Ö Cooper C McCloskey E Kanis JA Ohlsson C Mellström D Johansson H Falls predict fractures independently of FRAX probability: a meta-analysis of the Osteoporotic Fractures in Men (MrOS) Study J Bone Miner Res 2018 33 510 516 29220072 PMC5842893
  91. [95]Harvey NC Johansson H Odén A Karlsson MK Rosengren BE Ljunggren Ö Cooper C McCloskey E Kanis JA Ohlsson C Mellström D FRAX predicts incident falls in elderly men. Findings from MrOs Sweden Osteoporos Int 2016 27 267 274 26391036
  92. [96]Oliver D Connelly JB Victor CR Shaw FE Whitehead A Genc Y Vanoli A Martin FC Gosney MA Strategies to prevent falls and fractures in hospitals and care homes and effect of cognitive impairment: systematic review and meta-analyses BMJ 2007 334 82 17158580 PMC1767306
  93. [97]Kayan K Johansson H Odén A Vasireddy S Pande K Orgee J Kanis JA McCloskey EV Can fall risk be incorporated into fracture risk assessment algorithms: a pilot study of responsiveness to clodronate Osteoporos Int 2009 20 2055 2061 19436939
  94. [99]Michael YL Whitlock EP Lin JS Fu R O’Connor EA Gold R Primary care-relevant interventions to prevent falling in older adults: a systematic evidence review for the U.S. Preventive Services Task Force Ann Intern Med 2010 153 815 825 21173416
  95. [100]Kanis JA Johansson H Odén A McCloskey EV Guidance for the adjustment of FRAX according to the dose of glucocorticoids Osteoporos Int 2011 22 809 816 21229233
  96. [101]Leslie WD Lix LM Johansson H Odén A McCloskey E Kanis JA Spine-hip discordance and fracture risk assessment: a physician-friendly FRAX enhancement Osteoporos Int 2011 22 839 847 20959961
  97. [102]Johansson H, Kanis JA, Odén A, Leslie WD, Fujiwara S, Glüer CC, Kroger H, LaCroix AZ, Lau E, Melton LJ 3rd, Eisman JA, O’Neill TW, Goltzman D, Reid DM, McCloskey E (2014) Impact of femoral neck and lumbar spine BMD discordances on FRAX probabilities in women: a meta-analysis of international cohorts. Calcif Tiss Int 95: 428–435 PMC4361897 25187239
  98. [103]Leslie WD Shevroja E Johansson H McCloskey EV Harvey NC Kanis JA Hans D Risk-equivalent T-score adjustment using lumbar spine trabecular bone score (TBS): the Manitoba BMD Registry Osteoporos Int 2018 29 751 758 29392355 PMC5993188
  99. [104]Leslie WD Lix LM Morin SN Johansson H Odén A McCloskey EV Kanis JA Adjusting hip fracture probability in men and women using hip axis length: the Manitoba Bone Density Database J Clin Densitom 2015 19 326 331 26257267
  100. [105]Masud T, Binkley N, Boonen S, Hannan MT. on behalf of the FRAX Position Conference members (2011) Can falls and frailty be used in FRAX? J Clin Densitom 14: 194–204 21810525
  101. [106]Johansson H Odén A Lorentzon M McCloskey E Kanis JA Harvey NC Karlsson MK Mellstrom D Is the Swedish FRAX model appropriate for immigrants to Sweden? Osteoporos Int 2015 26 2617 2622 26018091
  102. [107]Leslie WD, Johansson H, McCloskey EV, Harvey NC, Kanis JA, Hans D (2018) Comparison of methods for improving fracture risk assessment in diabetes: the Manitoba BMD Registry. J Bone Miner Res 10.1002/jbmr.3538 [Epub ahead of print] PMC6193547 29953670 · DOI
  103. [108]Brennan SL Leslie WD Lix LM Johansson H Odén A McCloskey E Kanis JA FRAX provides robust fracture prediction regardless of socioeconomic status Osteoporos Int 2014 25 61 69 24190425
  104. [109]Leslie WD Orwoll EW Nielson CM Morin SN Majumdar SR Johansson H Odén A McCloskey EV Kanis JA Estimated lean mass and fat mass differentially affect femoral bone density and strength index but are not FRAX independent risk factors for fracture J Bone Miner Res 2014 29 2511 2519 24825359
  105. [110]Leslie WD Lix LM Johansson H Odén A McCloskey E Kanis JA Does osteoporosis therapy invalidate FRAX for fracture prediction? J Bone Miner Res 2012 27 1243 1251 22392538
  106. [111]Shepstone L Lenaghan E Cooper C Clarke S Fong-Soe-Khioe R Fordham R Gittoes N Harvey I Harvey N Heawood A Holland R Howe A Kanis J Marshall T O’Neill T Peters T Redmond N Torgerson D Turner D McCloskey E A randomized controlled trial of screening in the community to reduce fractures in older women—the SCOOP Study Lancet 2018 391 741 747 29254858
  107. [112]McCloskey E Johansson H Harvey NC Shepstone L Lenaghan E Fordham R Harvey I Howe A Cooper C Clarke S Gittoes N Heawood A Holland R Marshall T O’Neill TW Peters TJ Redmond N Torgerson D Kanis JA Management of patients with high baseline hip fracture risk by FRAX reduces hip fractures—a post hoc analysis from the SCOOP Study J Bone Miner Res 2018 33 1020 1026 29480960 PMC6004119
  108. [113]Ismail AA Cooper C Felsenberg D Varlow J Kanis JA Silman AJ O’Neill TW Number and type of vertebral deformities: epidemiological characteristics and relation to back pain and height loss. European Vertebral Osteoporosis Study Group Osteoporos Int 1999 9 206 213 10450408
  109. [114]Kanis JA McCloskey EV Johansson H Strom O Borgstrom F Odén A Case finding for the management of osteoporosis with FRAX—assessment and intervention thresholds for the UK Osteoporos Int 2008 19 1395 1408 18751937
  110. [115]Papaioannou A, Morin S, Cheung AM, Atkinson S, Brown JP, Feldman S, Hanley DA, Hodsman A, Jamal SA, Kaiser SM, Kvern B, Siminoski K, Leslie WD; Scientific Advisory Council of Osteoporosis Canada (2010) 2010 Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ 182: 1864–1873 PMC2988535 20940232
  111. [117]Kanis JA Johnell O Requirements for DXA for the management of osteoporosis in Europe Osteoporos Int 2005 16 229 238 15618996
  112. [118]Kanis JA McCloskey EV Harvey NC Johansson H Leslie WD Intervention thresholds and the diagnosis of osteoporosis J Bone Miner Res 2015 30 1747 1753 26390977
  113. [119]Grigorie D Sucaliuc A Johansson H Kanis JA McCloskey E Incidence of hip fracture in Romania and the development of a Romanian FRAX model Calcif Tissue Int 2013 92 429 436 23334302
  114. [120]Johansson H Azizieh F Al Ali N Alessa T Harvey NC McCloskey E Kanis JA FRAX- vs. T-score-based intervention thresholds for osteoporosis Osteoporos Int 2017 28 3099 3105 28782072 PMC5881885
  115. [121]Compston J Cooper A Cooper C Francis R Kanis JA Marsh D McCloskey EV Reid DM Selby P Wilkins M Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK Maturitas 2009 62 105 108 19135323
  116. [122]Tarantino U Iolascon G Cianferotti L Masi L Marcucci G Giusti F Marini F Parri S Feola M Rao C Piccirilli E Zanetti EB Cittadini N Alvaro R Moretti A Calafiore D Toro G Gimigliano F Resmini G Brandi ML Clinical guidelines for the prevention and treatment of osteoporosis: summary statements and recommendations from the Italian Society for Orthopaedics and Traumatology J Orthop Traumatol 2017 18 Suppl 1 3 36 29058226 PMC5688964
  117. [123]Lekamwasam S Adachi JD Agnusdei D Bilezikian J Boonen S Borgström F Cooper C Diez Perez A Eastell R Hofbauer LC Kanis JA Langdahl BL Lesnyak O Lorenc R McCloskey E Messina OD Napoli N Obermayer-Pietsch B Ralston SH Sambrook PN Silverman S Sosa M Stepan J Suppan G Wahl DA Compston JE A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis Osteoporos Int 2012 23 2257 2276 22434203
  118. [124]Kanis JA Stevenson M McCloskey EV Davis S Lloyd-Jones M Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis Health Technol Assess 2007 11 1 256 17311734
  119. [125]Johansson H Odén A Johnell O Jonsson B de Laet C Oglesby A McCloskey EV Kayan K Jalava T Kanis JA Optimization of BMD measurements to identify high risk groups for treatment—a test analysis J Bone Miner Res 2004 19 906 913 15190881
  120. [126]Johansson H Kanis JA Odén A Johnell O McCloskey E BMD, clinical risk factors and their combination for hip fracture prevention Osteoporos Int 2009 20 1675 1682 19291344
  121. [127]Kanis JA Adams J Borgstrom F Cooper C Jönsson B Preedy D Selby P Compston J The cost-effectiveness of alendronate in the management of osteoporosis Bone 2008 42 4 15 18156107
  122. [129]Shiroiwa T Sung YK Fukuda T Lang HC Bae SC Tsutani K International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? Health Econ 2010 19 422 437 19382128
  123. [130]Tosteson AN, Melton LJ, 3rd, Dawson-Hughes B, Baim S, Favus MJ, Khosla S, Lindsay RL (2008) Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int 19:437–447 PMC2729707 18292976
  124. [131]Leslie WD Morin S Lix LM Johansson H Odén A McCloskey E Kanis JA Fracture risk assessment without bone density measurement in routine clinical practice Osteoporos Int 2012 23 75 85 21850546
  125. [132]Leslie WD Majumdar SR Lix LM Johansson H Odén A McCloskey E Kanis JA High fracture probability with FRAX usually indicates densitometric osteoporosis: implications for clinical practice Osteoporos Int 2012 23 391 397 21365460
  126. [133]McCloskey EV Johansson H Harvey NC Compston J Kanis JA Access to fracture risk assessment by FRAX® and linked National Osteoporosis Guideline Group (NOGG) guidance in the UK—an analysis of anonymous website activity Osteoporos Int 2017 28 71 76 27438128
  127. [134]McCloskey E Kanis JA Johansson H Harvey N Odén A Cooper A Cooper C Francis RM Reid DM Marsh D Selby P Thompson F Hewitt S Compston J FRAX-based assessment and intervention thresholds—an exploration of thresholds in women aged 50 years and older in the UK Osteoporos Int 2015 26 2091 2099 26077380
  128. [135]Neuerburg C Stumpf U Schmidmaier R Kammerlander C Pfeilschifter J Mutschler W Bocker W Investigation and management of osteoporosis in aged trauma patients: a treatment algorithm adapted to the German guidelines for osteoporosis J Orthop Surg Res 2017 12 86 10.1186/s13018-017-0585-0 28595648 PMC5465580 · DOI
  129. [136]Harvey NC McCloskey E Kanis JA Compston J Cooper C Cost-effective but clinically inappropriate: new NICE intervention thresholds in osteoporosis (Technology Appraisal 464) Osteoporos Int 2018 29 1511 1513 29947864 PMC6037288
  130. [137]Kanis JA Odén A Johansson H McCloskey E Pitfalls in the external validation of FRAX Osteoporos Int 2012 23 423 431 22120907
  131. [138]Turner DA Khioe RFS Shepstone L Lenaghan E Cooper C Gittoes N Harvey NC Holland R Howe A McCloskey E O’Neill TW Torgerson D Fordham R The cost-effectiveness of screening in the community to reduce osteoporotic fractures in older women in the UK: economic evaluation of the SCOOP study J Bone Miner Res 2018 33 845 851 29470854 PMC5993187
  132. [139]Howe TE, Shea B, Dawson LJ, Downie F, Murray A, Ross C, Harbour RT, Caldwell LM, Creed G (2011) Exercise for preventing and treating osteoporosis in postmenopausal women. Cochrane Database Syst Rev CD000333 PMC12744941 21735380
  133. [140]Sañudo B, de Hoyo M, Del Pozo-Cruz J, Carrasco L, Del Pozo-Cruz B, Tejero S, Firth E (2017) Systematic review of the exercise effect on bone health: the importance of assessing mechanical loading in perimenopausal and postmenopausal women. Menopause 24: 1208–1216, 28538603
  134. [141]McMillan LB, Zengin A, Ebeling PR, Scott D (2017) Prescribing physical activity for the prevention and treatment of osteoporosis in older adults. Healthcare (Basel) 6;5(4). pii: E85. 10.3390/healthcare5040085 PMC5746719 29113119 · DOI
  135. [143]Sherrington C Michaleff ZA Fairhall N Paul SS Tiedemann A Whitney J Cumming RG Herbert RD Close JCT Lord SR Exercise to prevent falls in older adults: an updated systematic review and meta-analysis Br J Sports Med 2017 51 1750 1758 27707740
  136. [144]Tricco AC Thomas SM Veroniki AA Hamid JS Cogo E Strifler L Khan PA Robson R Sibley KM MacDonald H Riva JJ Thavorn K Wilson C Holroyd-Leduc J Kerr GD Feldman F Majumdar SR Jaglal SB Hui W Straus SE Comparisons of interventions for preventing falls in older adults: a systematic review and meta-analysis JAMA 2017 318 1687 1699 29114830 PMC5818787
  137. [145]El-Khoury F Cassou B Charles MA Dargent-Molina P The effect of fall prevention exercise programmes on fall induced injuries in community dwelling older adults: systematic review and meta-analysis of randomised controlled trials BMJ 2013 347 f6234 24169944 PMC3812467
  138. [146]Jepsen DB Thomsen K Hansen S Jørgensen NR Masud T Ryg J Effect of whole-body vibration exercise in preventing falls and fractures: a systematic review and meta-analysis BMJ Open 2017 7 12 e018342 29289937 PMC6027066
  139. [147]Sawka AM Boulos P Beattie K Thabane L Papaioannou A Gafni A Cranney A Zytaruk N Hanley DA Adachi JD Do hip protectors decrease the risk of hip fracture in institutional and community-dwelling elderly? A systematic review and meta-analysis of randomized controlled trials Osteoporos Int 2005 16 1461 1474 15990949
  140. [148]Parker MJ Gillespie WJ Gillespie LD Effectiveness of hip protectors for preventing hip fractures in elderly people: systematic review BMJ 2006 332 571 574 16513687 PMC1397761
  141. [149]Kiel DP Magaziner J Zimmerman S Ball L Barton BA Brown KM Stone JP Dewkett D Birge SJ Efficacy of a HIP protector to prevent HIP fracture in nursing home residents: the HIP PRO randomized controlled trial JAMA 2007 298 413 422 17652295
  142. [150]Gillespie WJ, Gillespie LD, Parker MJ (2010) Hip protectors for preventing hip fractures in older people. Cochrane Database Syst Rev CD001255 16034859
  143. [151]Rizzoli R Nutritional aspect of bone health Best Pract Res Clin Endocrinol Metab 2014 28 795 808 25432353
  144. [153]Harvey NC Biver E Kaufman JM Bauer J Branco J Brandi ML Bruyère O Coxam V Cruz-Jentoft A Czerwinski E Dimai H Fardellone P Landi F Reginster JY Dawson-Hughes B Kanis JA Rizzoli R Cooper C The role of calcium supplementation in healthy musculoskeletal ageing: an expert consensus meeting of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Foundation for Osteoporosis (IOF) Osteoporos Int 2017 28 447 462 27761590 PMC5274536
  145. [155]Weaver CM Alexander DD Boushey CJ Dawson-Hughes B Lappe JM LeBoff MS Liu S Looker AC Wallace TC Wang DD Calcium plus vitamin D supplementation and risk of fractures: an updated meta-analysis from the National Osteoporosis Foundation Osteoporos Int 2016 27 367 376 26510847 PMC4715837
  146. [156]Zhao JG Zeng XT Wang J Liu L Association between calcium or vitamin D supplementation and fracture incidence in community-dwelling older adults: a systematic review and meta-analysis JAMA 2017 318 2466 2482 29279934 PMC5820727
  147. [157]Bolland MJ Grey A Avenell A Gamble GD Reid IR Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women’s Health Initiative limited access dataset and meta-analysis BMJ 2011 342 d2040 21505219 PMC3079822
  148. [158]Nordin BE Lewis JR Daly RM Horowitz J Metcalfe A Lange K Prince RL The calcium scare—what would Austin Bradford Hill have thought? Osteoporos Int 2011 22 3073 3077 21633827
  149. [159]Bolland MJ Grey A Reid IR Re: The calcium scare: what would Austin Bradford Hill have thought? Osteoporos Int 2011 22 3079 3080 21901474
  150. [160]Bolland MJ Grey A Reid IR Misclassification does not explain increased cardiovascular risks of calcium supplements J Bone Miner Res 2012 27 959 22434645
  151. [161]Lewis JR Calver J Zhu K Flicker L Prince RL Calcium supplementation and the risks of atherosclerotic vascular disease in older women: results of a 5-year RCT and a 4.5-year follow-up J Bone Miner Res 2011 26 35 41 20614474
  152. [162]Lewis JR Zhu K Prince RL Adverse events from calcium supplementation: relationship to errors in myocardial infarction self-reporting in randomized controlled trials of calcium supplementation J Bone Miner Res 2012 27 719 722 22139587
  153. [163]Lewis JR Zhu K Prince RL Response to: Misclassification does not explain increased cardiovascular risks of calcium supplements J Bone Miner Res 2012 27 960 961 22434645
  154. [164]Hiligsmann M Ben Sedrine W Bruyère O Evers SM Rabenda V Reginster JY Cost-effectiveness of vitamin D and calcium supplementation in the treatment of elderly women and men with osteoporosis Europ J Public Health 2015 25 20 25 25096255
  155. [165]Bischoff-Ferrari HA Dawson-Hughes B Staehelin HB Orav JE Stuck AE Theiler R Wong JB Egli A Kiel DP Henschkowski J Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials BMJ 2009 339 b3692 19797342 PMC2755728
  156. [166]Bischoff-Ferrari HA Willett WC Orav EJ Lips P Meunier PJ Lyons RA Flicker L Wark J Jackson RD Cauley JA Meyer HE Pfeifer M Sanders KM Stähelin HB Theiler R Dawson-Hughes B Pooled analysis of vitamin D dose requirements for fracture prevention N Engl J Med 2012 367 40 49 22762317
  157. [167]Smith H Anderson F Raphael H Maslin P Crozier S Cooper C Effect of annual intramuscular vitamin D on fracture risk in elderly men and women—a population-based, randomized, double-blind, placebo-controlled trial Rheumatol (Oxford) 2007 46 1852 1857 17998225
  158. [168]Sanders KM Stuart AL Williamson EJ Simpson JA Kotowicz MA Young D Nicholson GC Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial JAMA 2010 303 1815 1822 20460620
  159. [169]Bischoff-Ferrari HA Dawson-Hughes B Orav EJ Staehelin HB Meyer OW Theiler R Dick W Willett WC Egli A Monthly high-dose vitamin D treatment for the prevention of functional decline: a randomized clinical trial JAMA Intern Med 2016 176 175 183 26747333
  160. [170]Smith LM Gallagher JC Suiter C Medium doses of daily vitamin D decrease falls and higher doses of daily vitamin D3 increase falls: a randomized clinical trial J Steroid Biochem Mol Biol 2017 173 317 322 28323044 PMC5595629
  161. [172]Rizzoli R Dairy products, yogurts, and bone health Am J Clin Nutr 2014 99 5 Suppl 1256S 1262S 24695889
  162. [173]Rozenberg S Body JJ Bruyère O Bergmann P Brandi ML Cooper C Devogelaer JP Gielen E Goemaere S Kaufman JM Rizzoli R Reginster JY Effects of dairy products consumption on health: benefits and beliefs—a commentary from the Belgian Bone Club and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases Calcif Tissue Int 2016 98 1 17 26445771 PMC4703621
  163. [174]Durosier-Izart C Biver E Merminod F van Rietbergen B Chevalley T Herrmann FR Ferrari SL Rizzoli R Peripheral skeleton bone strength is positively correlated with total and dairy protein intakes in healthy postmenopausal women Am J Clin Nutr 2017 105 513 525 28077378
  164. [175]Langsetmo L Shikany JM Burghardt AJ Cawthon PM Orwoll ES Cauley JA Taylor BC Schousboe JT Bauer DC Vo TN Ensrud KE Osteoporotic Fractures in Men (MrOS) Study Research Group High dairy protein intake is associated with greater bone strength parameters at the distal radius and tibia in older men: a cross-sectional study Osteoporos Int 2018 29 69 77 29063213 PMC5772967
  165. [176]Feskanich D Meyer HE Fung TT Bischoff-Ferrari HA Willett WC Milk and other dairy foods and risk of hip fracture in men and women Osteoporos Int 2018 29 385 396 29075804 PMC6814380
  166. [177]Laird E Molloy AM McNulty H Ward M McCarroll K Hoey L Hughes CF Cunningham C Strain JJ Casey MC Greater yogurt consumption is associated with increased bone mineral density and physical function in older adults Osteoporos Int 2017 28 2409 2419 28462469
  167. [178]Rizzoli R Biver E Effects of fermented milk products on bone Calcif Tissue Int 2018 102 489 500 28823001
  168. [179]Biver E Durosier-Izart C Merminod F Chevalley T van Rietbergen B Ferrari SL Rizzoli R Fermented dairy products consumption is associated with attenuated cortical bone loss independently of total calcium, protein, and energy intakes in healthy postmenopausal women Osteoporos Int 2018 29 1771 1782 29725715
  169. [180]Chen GC Wang Y Tong X Szeto IMY Smit G Li ZN Qin LQ Cheese consumption and risk of cardiovascular disease: a meta-analysis of prospective studies Eur J Nutr 2017 56 2565 2575 27517544
  170. [181]Ethgen O, Hiligsmann M, Burlet N, Reginster JY (2015) Public health impact and cost-effectiveness of dairy products supplemented with vitamin D in prevention of osteoporotic fractures. Arch Public Health 2015(14):73–48 PMC4677432 26668740
  171. [182]Ethgen O Hiligsmann M Burlet N Reginster JY Cost-effectiveness of personalized supplementation with vitamin D-rich dairy products Osteoporos Int 2016 27 301 308 26395885 PMC4715839
  172. [183]Hiligsmann M Neuprez A Buckinx F Locquet M Reginster JY A scoping review of the public health impact of vitamin D-fortified dairy products for fracture prevention Arch Osteoporos 2017 12 57 10.1007/s11657-017-0352-1 28634891 PMC5486688 · DOI
  173. [184]Hiligsmann M Reginster JY The projected public health and economic impact of vitamin D fortified dairy products for fracture prevention in France Expert Rev Pharmacoecon Outcomes Res 2017 7 1 5 28862051
  174. [185]Saito T Sterbenz JM Malay S Zhong L MacEachern MP Chung KC Effectiveness of anti-osteoporotic drugs to prevent secondary fragility fractures: systematic review and meta-analysis Osteoporos Int 2017 28 3289 3300 28770272
  175. [186]Kanis JA Cooper C Rizzoli R Abrahamsen B Al-Daghri NM Brandi ML Cannata-Andia J Cortet B Dimai HP Ferrari S Hadji P Harvey NC Kraenzlin M Kurth A McCloskey E Minisola S Thomas T Reginster JY Identification and management of patients at increased risk of osteoporotic fracture: outcomes of an ESCEO expert consensus meeting Osteoporos Int 2017 28 2023 2034 28451733 PMC5483332
  176. [187]Love RR Mazess RB Barden HS Epstein S Newcomb PA Jordan VC Carbone PP DeMets DL Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer N Engl J Med 1992 326 852 856 1542321
  177. [188]Ettinger B Black DM Mitlak BH Knickerbocker RK Nickelsen T Genant HK Christiansen C Delmas PD Zanchetta JR Stakkestad J Glüer CC Krueger K Cohen FJ Eckert S Ensrud KE Avioli LV Lips P Cummings SR Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators JAMA 1999 282 637 645 10517716
  178. [189]Delmas PD Genant HK Crans GG Stock JL Wong M Siris E Adachi JD Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial Bone 2003 33 522 532 14555255
  179. [190]Cummings SR Eckert S Krueger KA Grady D Powles TJ Cauley JA Norton L Nickelsen T Bjarnason NH Morrow M Lippman ME Black D Glusman JE Costa A Jordan VC The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation JAMA 1999 281 2189 2197 10376571
  180. [191]Vogel VG Costantino JP Wickerham DL Cronin WM Cecchini RS Atkins JN Bevers TB Fehrenbacher L Pajon ER Jr Wade JL 3rd Robidoux A Margolese RG James J Lippman SM Runowicz CD Ganz PA Reis SE McCaskill-Stevens W Ford LG Jordan VC Wolmark N Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial JAMA 2006 295 2727 2741 16754727
  181. [192]Mosca L Barrett-Connor E Wenger NK Collins P Grady D Kornitzer M Moscarelli E Paul S Wright TJ Helterbrand JD Anderson PW Design and methods of the Raloxifene Use for The Heart (RUTH) study Am J Cardiol 2001 88 392 395 11545760
  182. [193]Barrett-Connor E Mosca L Collins P Geiger MJ Grady D Kornitzer M McNabb MA Wenger NK Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women N Engl J Med 2006 355 125 137 16837676
  183. [194]Kanis JA Johnell O Black DM Downs RW Jr Sarkar S Fuerst T Secrest RJ Pavo I Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial Bone 2003 33 293 300 13678769
  184. [195]Kanis JA Johansson H Odén A McCloskey EV A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX Bone 2010 47 729 735 20601292
  185. [196]Silverman SL Christiansen C Genant HK Vukicevic S Zanchetta JR de Villiers TJ Constantine GD Chines AA Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial J Bone Miner Res 2008 23 1923 1934 18665787
  186. [197]Silverman SL Chines AA Kendler DL Kung AW Teglbjaerg CS Felsenberg D Mairon N Constantine GD Adachi JD Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study Osteoporos Int 2012 23 351 363 21779819
  187. [198]Palacios S Silverman SL de Villiers TJ Levine AB Goemaere S Brown JP De Cicco Nardone F Williams R Hines TL Mirkin S Chines AA Bazedoxifene Study Group A 7-year randomized, placebo-controlled trial assessing the long-term efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis: effects on bone density and fracture Menopause 2015 22 806 813 25668306
  188. [199]Ellis AG Reginster JY Luo X Bushmakin AG Williams R Sutradhar S Mirkin S Jansen JP Indirect comparison of bazedoxifene vs oral bisphosphonates for the prevention of vertebral fractures in postmenopausal osteoporotic women Curr Med Res Opin 2014 30 1617 1626 24773456
  189. [200]Ellis AG Reginster JY Luo X Cappelleri JC Chines A Sutradhar S Jansen JP Bazedoxifene versus oral bisphosphonates for the prevention of nonvertebral fractures in postmenopausal women with osteoporosis at higher risk of fracture: a network meta-analysis Value Health 2014 17 424 432 24969003 PMC5583519
  190. [201]Kanis JA Johansson H Odén A McCloskey EV Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX Bone 2009 44 1049 1054 19254788
  191. [202]de Villiers TJ Chines AA Palacios S Lips P Sawicki AZ Levine AB Codreanu C Kelepouris N Brown JP Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial Osteoporos Int 2011 22 567 576 20535606
  192. [203]Umland EM Karel L Santoro N Bazedoxifene and conjugated equine estrogen: a combination product for the management of vasomotor symptoms and osteoporosis prevention associated with menopause Pharmacotherapy 2016 36 548 561 27027527
  193. [204]Hadji P Ryan KA Yu CR Mirkin S Komm BS CE/BZA effects on bone and quality of life in European postmenopausal women: a pooled analysis Climacteric 2016 19 482 487 27631562
  194. [205]Rizzoli R Bisphosphonates for post-menopausal osteoporosis: are they all the same? Quart J Med 2011 104 281 300 21258058
  195. [206]Khan SA Kanis JA Vasikaran S Kline WF Matuszewski BK McCloskey EV Beneton MN Gertz BJ Sciberras DG Holland SD Orgee J Coombes GM Rogers SR Porras AG Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis J Bone Miner Res 1997 12 1700 1707 9333131
  196. [207]Black DM Cummings SR Karpf DB Cauley JA Thompson DE Nevitt MC Bauer DC Genant HK Haskell WL Marcus R Ott SM Torner JC Quandt SA Reiss TF Ensrud KE Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group Lancet 1996 348 1535 1541 8950879
  197. [208]Cranney A Guyatt G Griffith L Wells G Tugwell P Rosen C Meta-analyses of therapies for postmenopausal osteoporosis. IX: summary of meta-analyses of therapies for postmenopausal osteoporosis Endocr Rev 2002 23 570 578 12202472
  198. [209]Stevenson M Jones ML De Nigris E Brewer N Davis S Oakley J A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis Health Technol Assess 2005 9 1 160 15929857
  199. [210]Cummings SR Black DM Thompson DE Applegate WB Barrett-Connor E Musliner TA Palermo L Prineas R Rubin SM Scott JC Vogt T Wallace R Yates AJ LaCroix AZ Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial JAMA 1998 280 2077 2082 9875874
  200. [211]Axelsson KF Wallander M Johansson H Lundh D Lorentzon M Hip fracture risk and safety with alendronate treatment in the oldest-old J Intern Med 2017 282 546 559 28857352

200 of 340 shown

Authors
on behalf of the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF), Kanis, J. A., Cooper, C., Rizzoli, R., & Reginster, J.-Y.
Affiliations
  • University of Oxford (GB)
  • University Hospital of Geneva (CH)
  • University of Liège (BE)
ORCID
Venue
Osteoporosis International
Publisher
Springer Science and Business Media LLC
Published
2018-10-15
Volume
30
Issue
1
Pages
3-44
ISSN
  • 0937-941X (ISSN-L)
  • 1433-2965
DOI
10.1007/s00198-018-4704-5
PMC
PMC7026233
OpenAlex
W4253165656
Cited by
1,900
References
373
Citations by year
2026: 237 · 2025: 247 · 2024: 309 · 2023: 304 · 2022: 268 · 2021: 228 · 2020: 190 · 2019: 85 · 2018: 8 · 2017: 4 · 2016: 8 · 2015: 2 · 2014: 4 · 2012: 1
FWCI
140.31
Type
journal article
Language
en
Update notices
Open access
Licence
Locations
  • Osteoporosis International (publishedVersion, cc-by-nc)
  • ePrints Soton (University of Southampton) (acceptedVersion)
  • ORBi (University of Liège) (submittedVersion)
Funders
  • National Institute for Health and Care Research (10/33/04, NF-SI-0508-10082, NF-SI-0513-10085)
  • Medical Research Council (MC_UU_12011/2, MC_UU_12011/1)
Topics
  • Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
  • Health Sciences › Medicine › Surgery › Hip and Femur Fractures
Keywords
osteoporosis, postmenopausal women, fracture risk assessment, bone mineral density, FRAX, fracture liaison service, secondary fracture prevention, treatment monitoring, bone microarchitecture, dietary intake, health economics, case finding

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review